Ibrutinib and venetoclax target distinct subpopulations of CLL cells: implication for residual disease eradication.
Lu P, Wang S, Franzen CA, Venkataraman G, McClure R, Li L, Wu W, Niu N, Sukhanova M, Pei J, Baldwin DA, Nejati R, Wasik MA, Khan N, Tu Y, Gao J, Chen Y, Ma S, Larson RA, Wang YL.
Lu P, et al. Among authors: pei j.
Blood Cancer J. 2021 Feb 18;11(2):39. doi: 10.1038/s41408-021-00429-z.
Blood Cancer J. 2021.
PMID: 33602908
Free PMC article.